Clinical Trials

IntReALL HR 2010

International study for treatment of childhood Relapsed high risk ALL (HR-ALL) 2010: A randomized Phase II Study

Leukaemia

This study will assess the effectiveness of adding the drug bortezomib to the standard drug treatment for high risk (HR) acute lymphoblastic leukaemia (ALL) in children and adolescents who have relapsed. During the first month of relapse treatment, the child or adolescent will be randomly allocated to receive standard treatment with or without bortezomib.  This will demonstrate if inclusion of bortezomib will improve the chance of a complete response if provided in first month of relapse treatment.

Disease Stage: Relapse

Patient Age Range: <18 years

Sample Size: 100-250

Trial Sponsors:

  • International: Charite University Medicine Berlin
  • National: ANZCHOG

Read more at Clinical Trial Registry

ANZCHOG acknowledges the valuable support of IntReALL-HR by The Kids Cancer Project.

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168